Start here if you're new
what it is
Rapid Micro sells machines and lab tools that help drugmakers find contamination faster, so factories can release medicine sooner.
how it gets paid
Last year Rapid Micro made $34M in revenue. Growth Direct systems was the main engine at $13.6M, or 40% of sales.
why it's growing
Revenue grew 19.7% last year. Quarterly EPS moved from -$0.39 in Q4 2023 to -$0.22 in Q4 2024.
what just happened
The cleanest takeaway is that quarterly EPS improved to -$0.22 in Q4 2024 from -$0.39 a year earlier, even with the business still losing money.
At a glance
C++ balance sheet — some cracks in the foundation
-$1.08 fy2024 eps est
$2B fy2026 rev est
n/a operating margin
1.5 beta
xvary composite: 32/100 — weak
What they do
Rapid Micro sells machines and lab tools that help drugmakers find contamination faster, so factories can release medicine sooner.
Drug manufacturing hates surprises. If your contamination test is tied into a regulated workflow, ripping it out is painful and risky. Rapid Micro has just 163 employees, but its Growth Direct system sits inside some of the most compliance-heavy labs on earth, where speed matters and switching is slow.
How they make money
$34M
annual revenue · their business grew +19.7% last year
Growth Direct systems
$13.6M
+37.0%
service and support
$10.2M
+19.7%
consumables
$6.8M
+19.7%
software and other
$3.4M
+19.7%
The products that matter
automated microbial testing platform
Growth Direct System
$33.6M product revenue · record Q4
this is the business today. product sales reached $33.6M in 2025, and Q4 revenue hit a record $11.3M after a 37% jump. if placements slow, the whole story slows with them.
current engine
cloud software and analytics layer
Cloud-Native Software Platform
planned H2 2026 launch
this matters because the current business runs on roughly 20% gross margin. management needs software to add recurring revenue and improve unit economics from here.
margin bet
service and support
Service & Other
$0.3M · flat
this line is still tiny at $0.3M. that's the quiet part loud: the higher-quality revenue stream is not carrying the business yet.
still tiny
Key numbers
-$1.08
fy2024 eps est
$2B
fy2026 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $23M (15% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for RPID right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The cleanest takeaway is that quarterly EPS improved to -$0.22 in Q4 2024 from -$0.39 a year earlier, even with the business still losing money.
Quarterly EPS moved from -$0.39 in Q4 2023 to -$0.22 in Q4 2024, based on the quarterly history provided. Annual revenue still came in at just $34M, so this is progress on a very small base.
$34M
annual revenue
$0.22
q4 eps
n/a
operating margin
the number that mattered
Q4 EPS of -$0.22 matters most because it shows losses are narrowing, from -$0.39 a year earlier, even before this business has reached real scale.
source: company filings and quarterly history, 2024
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is failing to turn Growth Direct placements into a profitable installed base.
med
thin gross margin leaves no cushion
Roughly 20% gross margin is light for a company still paying for product development, commercialization, and a software push. When the base is this small, execution mistakes are expensive fast.
At $33.6M of annual revenue, even decent growth can still leave the model cramped if margin does not improve.
med
the software thesis is still a promise
The cloud-native software platform is planned for H2 2026. That is central to the better-margin narrative, and today it is still launch timing, not booked revenue.
If the launch slips or adoption disappoints, the stock is left with a hardware-heavy business the market was already hoping would evolve.
med
order timing can swing the quarter
Rapid Micro sells expensive systems into pharma and biotech manufacturing. That is a real market, but it is not a broad funnel. A few delayed purchases can distort growth when one quarter is only $11.3M.
Lumpy order flow means headline growth can look strong one quarter and fragile the next.
med
balance-sheet quality is not bailing you out
C++ balance sheet grade, a risk rank of 5, price stability of 5 / 100, and $23M in long-term debt do not give you much room for operational misses.
If revenue comes in below the $37M–$41M guide, the conversation shifts from growth to financing risk very fast.
A miss against the $37M–$41M 2026 guide or a delay to the planned H2 2026 software launch would hit the two parts of the thesis at once: growth and margin improvement.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
2026 revenue guide: $37M–$41M
This is the cleanest scorecard on the page. Hit it and the growth case stays alive. Miss it and investors start treating the Q4 beat like a one-quarter event.
calendar
planned H2 2026 software launch
The timing matters because software is the margin expansion argument. If the date moves right, the thesis moves with it.
trend
gross margin versus revenue growth
More sales help. Better mix helps more. You want to see growth and margin rise together, not one doing all the work while the other stays stuck near 20%.
risk
balance-sheet pressure
C++ balance sheet grade, $23M in long-term debt, and no earnings mean small misses matter. This company does not have the luxury of sloppy quarters.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for RPID is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive